ERBB2 and neoplasm: For all patients, a significant association between in breast pathological response (ypT0-is versus ypT≥1) and tumor subtypes was observed in univariate analysis (Table 5): 14.2% for Luminal A (56/393), 28.8% for Luminal B HER2-negative (57/198), 49.0% for Luminal B HER2-positive (148/302), 67.7% for HER2-positive/ER-negative (149/220), and 49.1% for triple-negative tumors (252/513) (Figure 2).